The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|August 2, 2020
- Pharmaceutical Technology-08-02-2020
- Volume 44
- Issue 8
Aclar Edge Bottles and Vials
Aclar Edge from Honeywell is a pharmaceutical packaging solution for oral liquids for human health and sterile injectables for animal health applications.
Aclar Edge from Honeywell is a pharmaceutical packaging solution for oral liquids for human health and sterile injectables for animal health applications. Using the company’s proprietary multi-layer extrusion blow molding technology, Aclar Edge bottles and vials prolong shelf-life and efficacy for liquid dosage forms while promoting user safety during handling and administration.
With a moisture barrier, impact resistance, and a 75% weight reduction versus glass, Aclar Edge bottles and vials eliminate glass breakage, lessen drug particulate contamination, and reduce transportation cost. They also decrease the risk of leachables from the container closure systems.
Aclar Edge bottles and vials are available in sizes from 100 mL to 500 mL and can be configured in threaded or crimped finish.
Articles in this issue
about 6 years ago
Ensuring a Safe and Robust Supply of Pharma Materialsabout 6 years ago
Preparing for a Pandemicabout 6 years ago
A Great Manipulation: The Value of Engineering Particle Propertiesabout 6 years ago
Skipping Steps to BioPharma 4.0about 6 years ago
Assessing Data Integrity Risks in an R&D Environmentabout 6 years ago
Defining Drug Stability with Dissolution Testingabout 6 years ago
Reinvesting in European ManufacturingRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.